(firstQuint)A Study to Evaluate ABT-126 for the Treatment of Cognitive Deficits in Schizophrenia.

 This is a Phase 2 study designed to evaluate the safety and efficacy of ABT-126 in treating cognitive deficits in subjects with a diagnosis of schizophrenia.

 Eligible subjects will take study drug as an add-on treatment to their ongoing antipsychotic treatment regimen.

.

 A Study to Evaluate ABT-126 for the Treatment of Cognitive Deficits in Schizophrenia@highlight

This is a safety and efficacy study evaluating a experimental treatment for cognitive deficits in adults with schizophrenia.

